Literature DB >> 16005039

HIV-1 envelope pseudotyped viral vectors and infectious molecular clones expressing the same envelope glycoprotein have a similar neutralization phenotype, but culture in peripheral blood mononuclear cells is associated with decreased neutralization sensitivity.

Mark K Louder1, Anna Sambor, Elena Chertova, Tai Hunte, Sarah Barrett, Fallon Ojong, Eric Sanders-Buell, Susan Zolla-Pazner, Francine E McCutchan, James D Roser, Dana Gabuzda, Jeffrey D Lifson, John R Mascola.   

Abstract

Recombinant lentiviral vectors pseudotyped with heterologous HIV-1 envelope glycoproteins allow rapid and accurate measurement of antibody-mediated HIV-1 neutralization. However, the neutralization phenotypes of envelope pseudoviruses have not been directly compared to isogenic replication competent HIV-1. We produced pseudoviruses expressing three different HIV-1 envelope glycoproteins and subcloned the same three env genes into a replication competent NL4-3 molecular clone. For each of the antibodies tested, the neutralization dose-response curves of pseudoviruses and corresponding replication competent viruses were similar. Thus, envelope pseudoviruses can be used to study the anti-HIV-1 neutralizing antibody response. A single passage of replication competent virus derived from 293T cells through peripheral blood mononuclear cells (PBMC) caused a substantial decrease in sensitivity to neutralizing antibodies. This was associated with an increase in average virion envelope glycoprotein content of the PBMC-derived virus. Replication competent HIV-1 and isogenic envelope pseudoviruses have similar neutralization characteristics, but passage into PBMC is associated with decreased sensitivity to neutralization.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16005039     DOI: 10.1016/j.virol.2005.06.003

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  60 in total

1.  Proteomic and biochemical analysis of purified human immunodeficiency virus type 1 produced from infected monocyte-derived macrophages.

Authors:  Elena Chertova; Oleg Chertov; Lori V Coren; James D Roser; Charles M Trubey; Julian W Bess; Raymond C Sowder; Eugene Barsov; Brian L Hood; Robert J Fisher; Kunio Nagashima; Thomas P Conrads; Timothy D Veenstra; Jeffrey D Lifson; David E Ott
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

2.  Replication Capacity of Viruses from Acute Infection Drives HIV-1 Disease Progression.

Authors:  Philippe Selhorst; Carina Combrinck; Nonkululeko Ndabambi; Sherazaan D Ismail; Melissa-Rose Abrahams; Miguel Lacerda; Natasha Samsunder; Nigel Garrett; Quarraisha Abdool Karim; Salim S Abdool Karim; Carolyn Williamson
Journal:  J Virol       Date:  2017-03-29       Impact factor: 5.103

3.  Immunogenicity of recombinant human immunodeficiency virus type 1-like particles expressing gp41 derivatives in a pre-fusion state.

Authors:  Mikyung Kim; Zhisong Qiao; Jessica Yu; David Montefiori; Ellis L Reinherz
Journal:  Vaccine       Date:  2006-10-09       Impact factor: 3.641

4.  The neutralization sensitivity of viruses representing human immunodeficiency virus type 1 variants of diverse subtypes from early in infection is dependent on producer cell, as well as characteristics of the specific antibody and envelope variant.

Authors:  Nicholas M Provine; Valerie Cortez; Vrasha Chohan; Julie Overbaugh
Journal:  Virology       Date:  2012-02-25       Impact factor: 3.616

5.  Comparative characterization of transfection- and infection-derived simian immunodeficiency virus challenge stocks for in vivo nonhuman primate studies.

Authors:  Gregory Q Del Prete; Matthew Scarlotta; Laura Newman; Carolyn Reid; Laura M Parodi; James D Roser; Kelli Oswald; Preston A Marx; Christopher J Miller; Ronald C Desrosiers; Dan H Barouch; Ranajit Pal; Michael Piatak; Elena Chertova; Luis D Giavedoni; David H O'Connor; Jeffrey D Lifson; Brandon F Keele
Journal:  J Virol       Date:  2013-02-13       Impact factor: 5.103

6.  Truncating the gp41 Cytoplasmic Tail of Simian Immunodeficiency Virus Decreases Sensitivity to Neutralizing Antibodies without Increasing the Envelope Content of Virions.

Authors:  Ellen White; Fan Wu; Elena Chertova; Julian Bess; James D Roser; Jeffrey D Lifson; Vanessa M Hirsch
Journal:  J Virol       Date:  2018-01-17       Impact factor: 5.103

7.  Single genome amplification and standard bulk PCR yield HIV-1 envelope products with similar genotypic and phenotypic characteristics.

Authors:  Behzad Etemad; Melissa Ghulam-Smith; Oscar Gonzalez; Laura F White; Manish Sagar
Journal:  J Virol Methods       Date:  2015-02-11       Impact factor: 2.014

8.  Differential inhibition of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and TZM-bl cells by endotoxin-mediated chemokine and gamma interferon production.

Authors:  Anthony R Geonnotti; Miroslawa Bilska; Xing Yuan; Christina Ochsenbauer; Tara G Edmonds; John C Kappes; Hua-Xin Liao; Barton F Haynes; David C Montefiori
Journal:  AIDS Res Hum Retroviruses       Date:  2010-03       Impact factor: 2.205

9.  Neutralizing antibody titers conferring protection to macaques from a simian/human immunodeficiency virus challenge using the TZM-bl assay.

Authors:  Ronald Willey; Martha C Nason; Yoshiaki Nishimura; Dean A Follmann; Malcolm A Martin
Journal:  AIDS Res Hum Retroviruses       Date:  2010-01       Impact factor: 2.205

10.  sCD4-17b bifunctional protein: extremely broad and potent neutralization of HIV-1 Env pseudotyped viruses from genetically diverse primary isolates.

Authors:  Laurel A Lagenaur; Vadim A Villarroel; Virgilio Bundoc; Barna Dey; Edward A Berger
Journal:  Retrovirology       Date:  2010-02-16       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.